Drug updated on 11/13/2023

Dosage FormInjection (intravenous; 100 mg/10 mL)
Drug ClassInterleukin-5 antagonist monoclonal antibody
Ongoing and Completed


  • For add-on maintenance treatment of patients with severe asthma aged 18 years and older, and with an eosinophilic phenotype.

Product Monograph / Prescribing Information

Document TitleYearSource
Cinqair (reslizumab) Prescribing Information.2020Teva Respiratory, LLC, West Chester, PA

Systematic Reviews / Meta-Analyses

Document TitleYearSource
The effect of biologics in lung function and quality of life of patients with united airways disease: A systematic review.2024The Journal of Allergy and Clinical Immunology
Anti-IL-5 therapies for asthma. 2022Cochrane Database of Systematic Reviews
Tezepelumab compared with other biologics for the treatment of severe asthma: a systematic review and indirect treatment comparison. 2022Journal of Medical Economics
Real-world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: A systematic review and meta-analysis.2022Clinical and Experimental Allergy
The Clinical Efficacy of Type 2 Inflammation-Specific Agents Targeting Interleukins in Reducing Exacerbations in Severe Asthma: A Meta-Analysis.2022Yonsei Medical Journal
Effect of anti IL5, anti IL5R, anti IL13 therapy on asthma exacerbations: a network meta analysis.2020Lung
Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI guidelines - recommendations on the use of biologicals in severe asthma.2020Allergy
Monoclonal antibodies in type 2 asthma: a systematic review and network meta-analysis.2019Respiratory Research
Reslizumab compared with benralizumab in patients with eosinophilic asthma: a systematic literature review and network meta-analysis.2019The Journal of Allergy and Clinical Immunology: In Practice
Reslizumab and mepolizumab for moderate-to-severe poorly controlled asthma: an indirect comparison meta-analysis.2019Immunotherapy
Australian public assessment for reslizumab. 2018Australian Government: Department of Health
Biologic therapies for treatment of asthma associated with type 2 inflammation: effectiveness, value, and value-based price benchmarks.2018ICER
Efficacy and safety of anti-interleukin-5 therapy in patients with asthma: A pairwise and Bayesian network meta-analysis.2018International Immunopharmacology
Efficacy, adverse events, and inter-drug comparison of mepolizumab and reslizumab anti-IL-5 treatments of severe asthma – a systematic review and meta-analysis.2018European Clinical Respiratory Journal
Comparative Efficacy of Anti IL-4, IL-5 and IL-13 Drugs for Treatment of Eosinophilic Asthma: A Network Meta-analysis.2018Lung

Clinical Practice Guidelines